NewsRoom Articles - Page 111 of 220

TuesdayAug 02, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment

CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumor GBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is rising CNS recently received approval for a protocol amendment as part of its potentially pivotal study evaluating the efficacy and safety of Berubicin for the treatment of GBM The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy CNS…

MondayAug 01, 2022 11:15 am

With People in Sports and Military Service Worried About Long-Term Consequences of Traumatic Brain Injuries, Odyssey Health, Inc. (ODYY) Is Working to Offer Relief with PRV-002 Concussion Drug

Players and military service members often retire with debilitating traumatic brain injuries (“TBIs”), including concussions, that lessen the quality of life and present neurological problems as they continue to age Odyssey has developed PRV-002, a novel compound for treating concussion, and a novel breath-propelled nasal delivery device for delivering the drug deep into the nasal cavity The PRV-002 drug is expected to offer reprieve to people suffering from concussion by potentially preventing long-term consequences of the condition The drug is currently undergoing evaluation as part of a Phase I study that has so far shown that it is well tolerated…

MondayAug 01, 2022 9:47 am

Study Discovers Common Mechanism Behind Cancer Metastasis, Cardiovascular Disease

New research has identified a molecule that is involved in both cardiovascular disease and cancer metastasis. For cancer to become malignant, cells in tumors undergo various transformations that involve interactions between the tumor and an individual’s immune system. While most of the details involved in this process are unclear, evidence has shown that endothelial cell inflammation plays a key role in a tumor’s progression to metastasis. Endothelial cells usually form a layer lining the blood vessels in the body, helping regulate exchanges between the bloodstream and surrounding tissue. The study objective of the researchers at Hokkaido University was to look…

FridayJul 29, 2022 11:02 am

Study Suggests Coronavirus Vaccine May Be Linked to Temporary Changes in Menstrual Cycles

A new study has looked into the connection between menstrual health and vaccination against severe coronavirus infections. The researchers were focused on disproving reports that the coronavirus vaccine could affect menstruation cycles of women of reproductive age. These unfounded claims fostered vaccine skepticism among women as well as the general public, despite the lack of sufficient systematic research on the effects of the coronavirus vaccine on menstrual health. For their study, the researchers looked into the correlation between the SARS-CoV-2 infection and COVID vaccination with changes in the menstrual cycle features of more than 3,000 premenopausal healthcare workers. The researchers…

ThursdayJul 28, 2022 11:06 am

Study Finds That Introducing Some Foods to Infants Early Reduces Risks of Allergies

New research has shown that allowing infants to taste foods that contain wheat, milk, eggs and peanuts as early as the age of three months may decrease an infant’s risk of developing a food allergy. The study, which was led by Professor Karin C. Lødrup Carlsen of the Institute of Clinical Medicine at the University of Oslo, discovered that children who were introduced to these allergenic foods weren’t as likely to develop food allergies by the time they were three years old. For a long time now, the Norwegian Directorate of Health has advised that parents postpone introducing food to…

ThursdayJul 28, 2022 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance Enrollment for Phase 1/2a trial has already started Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/QfXhX) to proceed with its planned phase 1/2a first in-human clinical trial and has started enrollment (https://ibn.fm/HxkKp). The study is designed to evaluate Cybin’s proprietary deuterated…

ThursdayJul 28, 2022 9:00 am

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of players Currently, there is no FDA-approved medicinal treatment for helping people with concussion injuries Odyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injury Retired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board for Odyssey Health to help guide and promote public information regarding Odyssey’s treatment developments Wambach recently appeared on the Stock2Me podcast to discuss her interest in concussion research and her role on…

WednesdayJul 27, 2022 11:23 am

Researchers Develop Blood Test to Improve Tumor Diagnosis, Monitoring

Scientists at Massachusetts General Hospital have developed a tool that can detect additional mutations to help improve tumor diagnosis and monitoring. The scientists, who have in the past created a blood test to detect mutations in a glioma-linked gene, published their findings in “Clinical Cancer Research.” Gliomas are a common type of brain tumors that occur in adults. This advancement offers clinicians a strong tool to help uncover the presence of gliomas through the detection of mRNA in a patient’s blood. mRNA are pieces of the genetic material of tumor cells. Prior research was the first to highlight that this…

TuesdayJul 26, 2022 1:46 pm

Research Suggests How Individuals Can Control Unwanted Thoughts

Intrusive or unwanted thoughts are a common human experience. They often appear out of the blue, and in most cases, they tend to be unpleasant and unwanted. Unwanted thoughts and images can cause distress, especially when they force you to think about past traumatic or distressing events. Sometimes these thoughts can be associated with psychiatric disorders, including anxiety, depression and obsessive-compulsive disorder. Nevertheless, intrusive thoughts are a normal part of life despite the distress they can cause, and it is possible for you to control them. According to a study by the Hebrew University of Jerusalem, most people employ a…

TuesdayJul 26, 2022 9:00 am

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

PBS News Hour estimates that, for college students, concussions cost between $446 million and $1.5 billion annually, while for high school students the cost ranges from $5.4 billion to $19.2 billion Odyssey, through its flagship product, PRV-002, hopes to offer the first FDA-approved drug treatment for concussions Once approved, Odyssey is confident that PRV-w002 will bring relief to thousands of victims, reduce the cost of concussion treatment and allow victims to lead normal, healthy, and productive lives The company is currently scheduling a meeting with the FDA to present findings from the phase I trial, as it identifies phase II…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment

With People in Sports and Military Service Worried About Long-Term Consequences of Traumatic Brain Injuries, Odyssey Health, Inc. (ODYY) Is Working to Offer Relief with PRV-002 Concussion Drug

Study Discovers Common Mechanism Behind Cancer Metastasis, Cardiovascular Disease

Study Suggests Coronavirus Vaccine May Be Linked to Temporary Changes in Menstrual Cycles

Study Finds That Introducing Some Foods to Infants Early Reduces Risks of Allergies

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

Researchers Develop Blood Test to Improve Tumor Diagnosis, Monitoring

Research Suggests How Individuals Can Control Unwanted Thoughts

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search